274 related articles for article (PubMed ID: 16322336)
41. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
42. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
43. Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy.
Toivonen J; Tähtelä R; Laitinen K; Risteli J; Välimäki MJ
Eur J Endocrinol; 1998 Jun; 138(6):667-73. PubMed ID: 9678534
[TBL] [Abstract][Full Text] [Related]
44. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
[TBL] [Abstract][Full Text] [Related]
45. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.
Nuzzo V; Lupoli G; Esposito Del Puente A; Rampone E; Carpinelli A; Del Puente AE; Oriente P
Gynecol Endocrinol; 1998 Oct; 12(5):333-7. PubMed ID: 9859026
[TBL] [Abstract][Full Text] [Related]
46. Effects of levothyroxine therapy on bone mineral density and bone turnover markers in premenopausal women with thyroid cancer after thyroidectomy.
Bin-Hong D; Fu-Man D; Yu L; Xu-Ping W; Bing-Feng B
Endokrynol Pol; 2020; 71(1):15-20. PubMed ID: 31681976
[TBL] [Abstract][Full Text] [Related]
47. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma.
Kim CW; Hong S; Oh SH; Lee JJ; Han JY; Hong S; Kim SH; Nam M; Kim YS
J Bone Metab; 2015 Aug; 22(3):135-41. PubMed ID: 26389089
[TBL] [Abstract][Full Text] [Related]
48. [Bone mineral density in patients on long-term therapy with levothyroxine].
Korsić M; Cvijetić S; Dekanić-Ozegović D; Bolanća S; Kozić B
Lijec Vjesn; 1998 May; 120(5):103-5. PubMed ID: 9748785
[TBL] [Abstract][Full Text] [Related]
49. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
Franklyn JA; Betteridge J; Holder R; Sheppard MC
Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
[TBL] [Abstract][Full Text] [Related]
50. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.
Faber J; Galløe AM
Eur J Endocrinol; 1994 Apr; 130(4):350-6. PubMed ID: 8162163
[TBL] [Abstract][Full Text] [Related]
51. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
Kung AW; Yeung SS
J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
[TBL] [Abstract][Full Text] [Related]
52. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Heemstra KA; Hamdy NA; Romijn JA; Smit JW
Thyroid; 2006 Jun; 16(6):583-91. PubMed ID: 16839260
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of low bone mass in postmenopausal Kuwaiti women residents in the largest province of Kuwait.
Al-Shoumer KA; Nair V
Arch Osteoporos; 2012; 7():147-53. PubMed ID: 23225292
[TBL] [Abstract][Full Text] [Related]
54. Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen.
Schneider DL; Barrett-Connor EL; Morton DJ
JAMA; 1994 Apr; 271(16):1245-9. PubMed ID: 7848399
[TBL] [Abstract][Full Text] [Related]
55. Phalangeal quantitative ultrasound and bone mineral density in evaluating cortical bone loss: a study in postmenopausal women with primary hyperparathyroidism and subclinical iatrogenic hyperthyroidism.
Cipriani C; Romagnoli E; Scarpiello A; Angelozzi M; Montesano T; Minisola S
J Clin Densitom; 2009; 12(4):456-60. PubMed ID: 19815437
[TBL] [Abstract][Full Text] [Related]
56. A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.
McDermott MT; Perloff JJ; Kidd GS
Calcif Tissue Int; 1995 Jun; 56(6):521-5. PubMed ID: 7648478
[TBL] [Abstract][Full Text] [Related]
57. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
58. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
Paul TL; Kerrigan J; Kelly AM; Braverman LE; Baran DT
JAMA; 1988 Jun; 259(21):3137-41. PubMed ID: 3367489
[TBL] [Abstract][Full Text] [Related]
59. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
60. Bone density and mineral metabolism in thyroidectomized patients treated with long-term L-thyroxine.
Giannini S; Nobile M; Sartori L; Binotto P; Ciuffreda M; Gemo G; Pelizzo MR; D'Angelo A; Crepaldi G
Clin Sci (Lond); 1994 Nov; 87(5):593-7. PubMed ID: 7874849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
